Skye Bioscience Treats First Patient in Nimacimab Dose Study
In prior Phase 2a work, nimacimab combined with semaglutide delivered 22.3% mean weight loss at 52 weeks with no...
Priovant Launches New Brepocitinib Trial for LPP Hope
Priovant has begun enrolling a seamless Phase 2b/3 trial of brepocitinib in lichen planopilaris (LPP), with first patients dosed...
Promising New Eye Pain Trial Begins With First Patient Dosed
Pelthos Therapeutics has dosed the first patient in a Phase 1b/2a study of CT2000, a topical NaV1.7 inhibitor eye...
Tarsus Doses First Patient in Lyme Disease Prevention Trial
In earlier proof-of-concept work, a single oral dose of TP-05 (lotilaner) produced more than 90% tick mortality within 24...
Adcytherix Launches Phase 1 Trial, Strengthens Leadership
Adcytherix has dosed the first patient in a Phase 1a/b study of ADCX-020, an exatecan‑derived topoisomerase I inhibitor antibody‑drug...
Pheast Therapeutics Advances New Cancer Drug to Phase 1b Trial
Pheast Therapeutics has dosed the first patient in the Phase 1b combination portion of its ongoing Phase 1 study...
Actinogen Commences Xanamia Alzheimer’s Open-Label Trial
No efficacy data yet. Actinogen has initiated the open-label extension of its XanaMIA pivotal program in Alzheimer’s disease, dosing...
Vor Bio Doses First Patient in Phase 3 Sjögren’s Trial
RemeGen’s prior Phase 3 study in China of telitacicept in primary Sjögren’s disease reported statistically significant and clinically meaningful...
ZUSDURI Delivers 72.2% Durable Response in enVision Trial
ZUSDURI delivered a 79.6% complete response at three months in the pivotal Phase 3 ENVISION study, with a Kaplan-Meier–estimated...
Quantum, Allucent Advance Phase 2 Multiple Sclerosis Trial
Quantum BioPharma has signed a binding letter of intent with Allucent to run a planned Phase 2 study of...